DXCM vs MNKD: fair value comparison
DexCom, Inc. and MannKind Corporation · Updated 2026-08-31
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, MNKD currently sits closer to the top of our discount ranking.
| DXCM | MNKD | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $90.82 | $3.80 |
| 12-month range | $58.22–$87.31 | $2.54–$6.01 |
| Sector rank | #21 of 113 Healthcare | #17 of 113 Healthcare |
| Quality grade | A | A |
| Momentum grade | A | — |
| Leverage | Moderate | Low |
| Margin trend | Contracting | Expanding |
| Revenue growth | Strong | High |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | Mixed |
| DCF cross-check | Overvalued | Overvalued |
| 52-week position | The top quarter | The lower-middle quarter |
Full single-stock breakdowns: DXCM fair value analysis · MNKD fair value analysis